TY - JOUR
T1 - Co-morbidity and utilization of medical services by pain patients receiving opioid medications
T2 - Data from an insurance claims database
AU - Cicero, Theodore J.
AU - Wong, Gordon
AU - Tian, Yuhong
AU - Lynskey, Michael
AU - Todorov, Alexandre
AU - Isenberg, Keith
N1 - Funding Information:
This research was supported in part by NIH grant DA020791 and by unrestricted funds from the Department of Psychiatry, Washington University School of Medicine. No pharmaceutical company, or the insurance company providing the database, sponsored the research in any way. Theodore J. Cicero receives consulting fees from several pharmaceutical companies, none of which would have any particular interest in the outcome of these studies which were funded by an unrestricted grant from Washington University. Theodore J. Cicero had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Keith Isenberg and Gordon Wong provided the database and preliminary reports. Michael Lynskey, Alexandre Todorov, Yuhong Tian and Theodore Cicero designed the studies and prepared the reports. All of the above mentioned authors had full access to the data and assisted in the preparation of the datasets and this manuscript.
PY - 2009/7
Y1 - 2009/7
N2 - We used a large medical insurance claims database to identify three groups: chronic opioid use (>180 therapeutic days, N = 3726); acute opioid use (<10 therapeutic days, N = 37,108); and a non-opioid group (N = 337,366) who filed at least one insurance claim but none for opioids. Our results showed that although chronic opioid users represented only 0.65% of the total population, they filed 4.56% of all insurance claims, used 45% of all opioid analgesics and had much more physical and psychiatric co-morbidity than the acute opioid or non-opioid samples. Women were substantially over-represented (>63%) in the chronic pain group and used a much greater share of all medical services than males, especially as they grew older. Although our data suggest that chronic pain is optimally managed in a multidisciplinary patient- and gender-specific treatment plan, this was rarely the case with internists being the primary, and often only, physician seen. Moreover, our data suggest that opioids were often used for conditions in which they are generally not indicated (e.g. arthritis and headaches) or contraindicated by co-existing physical ailments (COPD). Finally, we conclude that adherence to the WHO analgesic ladder and other pain treatment guidelines was relatively infrequent: first, opioid extended release preparations which are ideally suited for chronic pain were used only in one in four patients; and, second, the selection of a weak (propoxyphene, codeine, and tramadol) or strong opioid (e.g. morphine and oxycodone) seemed to be driven by numerous factors not necessarily related to the intensity or duration of pain.
AB - We used a large medical insurance claims database to identify three groups: chronic opioid use (>180 therapeutic days, N = 3726); acute opioid use (<10 therapeutic days, N = 37,108); and a non-opioid group (N = 337,366) who filed at least one insurance claim but none for opioids. Our results showed that although chronic opioid users represented only 0.65% of the total population, they filed 4.56% of all insurance claims, used 45% of all opioid analgesics and had much more physical and psychiatric co-morbidity than the acute opioid or non-opioid samples. Women were substantially over-represented (>63%) in the chronic pain group and used a much greater share of all medical services than males, especially as they grew older. Although our data suggest that chronic pain is optimally managed in a multidisciplinary patient- and gender-specific treatment plan, this was rarely the case with internists being the primary, and often only, physician seen. Moreover, our data suggest that opioids were often used for conditions in which they are generally not indicated (e.g. arthritis and headaches) or contraindicated by co-existing physical ailments (COPD). Finally, we conclude that adherence to the WHO analgesic ladder and other pain treatment guidelines was relatively infrequent: first, opioid extended release preparations which are ideally suited for chronic pain were used only in one in four patients; and, second, the selection of a weak (propoxyphene, codeine, and tramadol) or strong opioid (e.g. morphine and oxycodone) seemed to be driven by numerous factors not necessarily related to the intensity or duration of pain.
KW - Opioid abuse
KW - Opioid dependence
UR - http://www.scopus.com/inward/record.url?scp=66049136043&partnerID=8YFLogxK
U2 - 10.1016/j.pain.2009.01.026
DO - 10.1016/j.pain.2009.01.026
M3 - Article
C2 - 19362417
AN - SCOPUS:66049136043
SN - 0304-3959
VL - 144
SP - 20
EP - 27
JO - Pain
JF - Pain
IS - 1-2
ER -